The role of probiotic agents in the prevention of seasonal incidence of ARVI
https://doi.org/10.21518/2079-701X-2013-2-46-50
Abstract
Acute respiratory viral infection, including influenza, remains one of the most pressing health, social and economic problems of our time. The reason is the significant seasonal prevalence of the diseases in all age groups, and a high risk of serious complications and possible exacerbation of pre-existing chronic conditions. Improving the efficacy of modern respiratory antiviral drugs remains a priority. Prevention of acute respiratory viral infection is still vital.
Keywords
респираторные инфекции,
грипп,
профилактика,
пробиотики,
3,
respiratory infections,
flu,
prevention,
probiotics,
Bion-3
About the Authors
N. L. Kunelskaya
ГБУЗ «МНПЦ оториноларингологии им. Л.И. Свержевского»
Russian Federation
Russian Federation
GN. Izotova
ГБУЗ «МНПЦ оториноларингологии им. Л.И. Свержевского»
Russian Federation
Russian Federation
M. V. Bessarab
ГБУЗ «МНПЦ оториноларингологии им. Л.И. Свержевского»
Russian Federation
Russian Federation
М. Nagibina
ГБУЗ «МНПЦ оториноларингологии им. Л.И. Свержевского»
Russian Federation
Russian Federation
Yu. V. Laryushkin
ГБУЗ «МНПЦ оториноларингологии им. Л.И. Свержевского»
Russian Federation
Russian Federation
References
1. Зайцев А.А., Синопальников А.И. Грипп: диагностика и лечение // РМЖ. 2008. Т.16. №22. С. 1494–1502.
2. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2011 году. Государственный доклад. М.: Федеральный центр Госсанэпиднадзора Минздрава России. 2011. 316 с. http://36.rospotrebnadzor.ru/download/gdrf/gdrf2011.pdf http://www.gripp.ru/info.aspx?id=69.
3. Neuzil K.M., Reed G.W., Mitchel E.F., Griffin M.R. Influenza-associated morbidity in young and middle– aged women // JAMA. 1999. Vol. 281. P. 901–907.
4. Thompson W.W. et al. Mortality associated with influenza and respiratory syncytial virus in the United States // JAMA. 2003. Vol. 289 (2). Р. 179–186.
5. Геппе Н.А. Справочник по педиатрии. М., 2002.
6. Коровина Н.А., Заплатников А.Л., Чебуркин А.В., Захарова И.Н. Часто и длительно болеющие дети: современные возможности иммунореабилитации: руководство для врачей. М., 2001.
7. World Health Organization. Influenza vaccines//Wkly Epidemiol. Rec. 2000; Vol. 75. Р. 281–288.
8. World Health Organization. Influenza vaccines//Wkly Epidemiol. Rec. 2002; Vol. 77. Р. 229.
9. Uphoff H., Cohen J.M., Fleming D., Noone A. Harmonisation of national influenza surveillance mor-bidity data from EISS: a simple index // Euro Surveill. 2003 Jul. Vol. 8 (7). Р. 156–164.
10. Palache A.M. Influenza vaccines. A reappraisal of their use // Drugs. 1997. Vol. 54. Р. 841–856.
11. WHO checklist for influenza pandemic preparedness planning. Geneva, World Health Organization, 2005.
12. Taipale T., Pienihäkkinen K., Isolauri E. et al. Bifidobacterium animalis subsp. lactis Bb-12 in reducing the risk of infections in infancy. Br J Nutr. 2010; 24: 1–7.
13. Cazzola M., Pham-Thi N., Kerihuel J.C., Durand H., Bohbot S. Efficacy of a synbiotic supplementation in the prevention of common winter diseases in children: a randomized, double-blind, placebo-con-trolled pilot study. Ther Adv Respir Dis. 2010; 4(5): 271–8.
14. Leyer G.J., Li S., Mubasher M.E., Reifer C., Ouwehand A.C. Probiotic effects on cold and influenza-like symptom incidence and duration in children. Pediatrics. 2009; 124(2): 172–9.
Review
For citations:
Kunelskaya NL, Izotova G, Bessarab MV, Nagibina , Laryushkin YV. The role of probiotic agents in the prevention of seasonal incidence of ARVI. Meditsinskiy sovet = Medical Council. 2013;(2):46-50. (In Russ.) https://doi.org/10.21518/2079-701X-2013-2-46-50
Views:
463
Email this article 